{"id":"NCT02577003","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)","officialTitle":"A Phase III, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial to Assess the Safety and Efficacy of Addition of Ipragliflozin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin Monotherapy in Addition to Diet and Exercise Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-09","primaryCompletion":"2016-11-25","completion":"2016-11-25","firstPosted":"2015-10-15","resultsPosted":"2018-03-07","lastUpdate":"2018-09-04"},"enrollment":143,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Ipragliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Sitagliptin","otherNames":["Januvia®, Tesavel®, Xelevia®, Ristaben®, Glactiv®"]}],"arms":[{"label":"Ipragliflozin + Sitagliptin","type":"EXPERIMENTAL"},{"label":"Placebo + Sitagliptin","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study to assess the safety and efficacy of the addition of ipragliflozin once daily in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise therapy. The primary hypothesis for this study is that the addition of ipragliflozin compared with placebo provides greater reduction in hemoglobin A1C (HbA1c) as assessed by change from baseline at Week 24.","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Ipragliflozin + Sitagliptin","deltaMin":-0.84,"sd":null},{"arm":"Placebo + Sitagliptin","deltaMin":-0.07,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["34033212"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":73},"commonTop":["Nasopharyngitis","Constipation","Contusion"]}}